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PSY67
VariationS in treatment PatternS and diSeaSe SeVeritY among 
PatientS with PSoriaSiS receiVing their FirSt Biologic in euroPean 
union
Narayanan S.1, Franceschetti A.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess the treatment patterns and current disease severity of 
patients with PsO receiving their first biologic in 5EU, namely, UK, Germany (DE), 
France (FR), Italy (IT) and Spain (SP). MethOds: A multi-country multi-center 
medical chart-review study of PsO patients was conducted among dermatologists 
in hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for practice-duration (3-30 yrs) and patient-volume (incl.> 2PsO biologic patients/
month) and recruited from a large panel to be geographically representative in 
each country. Physicians abstracted charts of next five consecutive biologic patients 
within each center/practice. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease severity. Results from patients 
on first biologic treatment were analyzed. Results: In 4Q2012, 225 physicians 
abstracted 924 eligible PsO patient charts; 690 (75%) were on their first biologic 
(mean-age:46.9yrs, female:36%). Geographic distribution-UK:18%, DE:21%, FR:19%, 
IT:21%, SP:21%. Time-to-1st biologic from diagnosis (months)/time-on-current bio-
logic (months) varied- UK:140/17, DE:119/10, FR:138/15, IT:103/18, SP:127/17. Top-4 
first-line biologic treatments observed were etanercept, adalimumab, infliximab 
and ustekinumab. Treatment experience prior to first biologic varied dramati-




FR:10%,IT:14%,SP:10%; Average # of flares in the past yr were: UK-1.0,DE-1.3,FR-
1.1,IT-1.0,SP-1.6. Mean current PASI scores were: UK-8,DE-20,FR-12,IT-18,SP-11. 
Current disease severity per physician judgment was (remission/mild/moder-
ate/severe): UK-45%/25%/20%/10%, DE-26%/19%/21%/35%, FR-42%/34%/15%/9%, 
IT-39%/19%/31%/11%, SP-44%/29%/26%/2%. Mean number of treatments prior to 
first biologic varied by current disease severity (remission/mild/moderate/severe): 
UK-2.7/3.1/2.6/3.1, DE-3.0/3.7/2.7/4.1, FR-2.2/2.6/2.2/2.4, IT-2.2/2.2/2.3/2.1, SP:2.4/2.
2/2.3/2.3. cOnclusiOns: Among PsO patients receiving their first biologic, treat-
ment patterns and disease severity varied across 5EU, with patients in Germany 
disproportionately experiencing higher disease burden. Factors influencing the 
observed variations in care and optimal therapeutic approaches (including treat-
ment sequencing) aligned with clinical guidelines to decrease patient disease bur-
den warrants scrutiny.
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PharmacotheraPY coStS oF multiPle mYeloma in the czech rePuBlic: 
a retroSPectiVe analYSiS
Baloghova K.1, Fuksa L.2
1Masaryk University, Brno, Czech Republic, 2General Health Insurance Company of the Czech 
Republic, Praha, Czech Republic
Objectives: In the Czech Republic there are three modern molecules available for 
the treatment of multiple myeloma: bortezomib, thalidomide and lenalidomide. 
In order to better understand this evolving specific market, analysis of consump-
tion trends has been conducted with emphasis on the molecules’ mutual influ-
ence. MethOds: Time-consumption curves of bortezomib, lenalidomide and 
thalidomide since 2009, based on the economic data of the General Health Insurance 
Company of the Czech Republic, were analyzed. While there was reimbursement for 
thalidomide in the first line treatment and bortezomib in the second line in 2009, 
we focused on and evaluated the impact of the launch of lenalidomide in 2009 (as 
a second line treatment). We also investigated the extension of reimbursement of 
bortezomib for the use in the first line in 2010. Results: The introduction of lena-
lidomide (2009) led to a rapid decline in thalidomide consumption within the next 
year, in contrast to bortezomib, the consumption of which appeared unaffected. 
Furthermore, also the consumption of thalidomide decreased profoundly following 
the extension of reimbursement conditions of bortezomib (2010). The overall relative 
reduction in thalidomide consumption observed within the two years between 2009 
and 2011 was 70%. cOnclusiOns: The presented retrospective analysis shows that 
the impact of myeloma treatment on payers’ financial budgets has increased nearly 
3-times in the last four years. The extension of reimbursement of bortezomib had a 
clear impact on the consumption of thalidomide, which was its supposed compara-
tor in the first line therapy. However, it appears that even though the introduction 
of lenalidomide did also significantly affect the consumption of thalidomid, it had 
no apparent impact on the use of bortezomib.
PSY70
aPPetite SuPPreSSantS: a drug utiliSation StudY
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
Objectives: To determine the prescribing and cost of appetite suppressants in a 
defined private sector patient population, as well as the prescribing of other medi-
cines to the patient sample. MethOds: A retrospective drug utilisation study was 
conducted on a medical insurance claims database in South Africa for 2010 and 
2011. No clinical information was available in the database. Results: In 2010, 37 
patients (86.49% females) were prescribed 44 appetite suppressants at a total cost 
of R9813.39, of which 75.0% were for phentermine. The average age of patients 
was 40.95 (SD= 12.37) years. In 2011, 27 patients (77.78% females) received 42 pre-
scriptions for appetite suppressants at a total cost of R9967.73. The average age of 
patients was 40.04 years (SD= 10.41) (females: 37.95 (SD= 7.76) years; males 47.33 
(SD= 10.52) years). Most products (80.95%) were for phentermine, followed by d-norp-
seudoephedrine (14.29%) and diethylpropion (4.76). Prescribing patterns in 2010 
and 2011 were similar. Appetite suppressants are strictly regulated in South Africa. 
biosimilars among their biologic-eligible RA patients, and their likelihood of use of 
biosimilars. Descriptive statistics are reported. Results: A total of 173 rheuma-
tologists participated in the survey. Years of experience practicing rheumatology 
was: < = 1yr:0%, 2-5yrs:6%, 6-10yrs:17%, 11-20yrs:42%, > 20yrs:32%. Geographic dis-
tribution of rheumatologists was: 5EU-58%, Brazil-23%, Japan-11% and China-9%. 
Mean RA patient-volume/year was 291 (5EU-329, Brazil-259, Japan-232 and China-
189). Overall, 47% of rheumatologists reported that they would prescribe a biosimi-
lar to their eligible RA patients “definitely or highly likely” (5EU:58%, Brazil:21%, 
Japan:47%, China:47%); 51% of rheumatologists reported that they would try using 
biosimilars for 1-2 yrs among a small group of patients in their practice before 
starting to use it in a majority of biologic-eligible RA patients in their practice 
(5EU:60%, Brazil:33%, Japan:42%, China:47%). The top-5 factors that would prevent 
them from using biosimilars were diverse across the countries (Overall/5EU/Brazil/
Japan/China): Doubts in similarity to original molecule 60%/63%/67%/47%/33%), 
inadequate safety/efficacy profile/data (53%/51%/51%/58%/60%), lack of long-term 
data (46%/51%/41%/32%/40%), lack of national guidelines recommending the use 
of biosimilars (37%/39%/31%/32%/47%) and lack of data from local country/market 
(31%/23%/41%/42%/47%). cOnclusiOns: Across markets, over half of the rheu-
matologists expressed concerns/reservations towards prescribing biosimilars to 
their eligible RA patients. While payer organizations look to biosimilars to contain 
costs and make medicines more affordable to RA patients in need, potential bar-
riers to biosimilar adoption may exist.
PSY65
BarrierS to Biologic theraPY uSe For autoimmune diSorderS in 
emerging marketS
Gross H.J.1, Vietri J.2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, Milan, Italy
Objectives: Biologic therapy is increasingly used to treat autoimmune dis-
orders in developed markets, but usage is still low in emerging markets. This 
analysis was conducted to identify factors associated with current use of bio-
logic medication among patients with autoimmune disorders in emerging mar-
kets. MethOds: Data were from the Brazil, China, and Russia National Health 
and Wellness Surveys, cross-sectional surveys representative of the total adult 
population (Brazil) or urban adult population (China and Russia) in each country, 
conducted in 2011 and 2012. Respondents self-reporting physician diagnosis of 
ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid 
arthritis, or ulcerative colitis and using a prescription medication (Rx) for at least 
one of those conditions were included; patients with missing data for any covari-
ate were excluded. Binomial logistic regression included the following predictors: 
age, sex, country, income, Charlson Comorbidity Index (CCI), body mass index 
(BMI), monthly out of pocket (OOP) costs for Rxs, fear of needles, condition severity, 
length of diagnosis, and type of treating physician. Results: Of 1,507 respondents 
included in the analysis, 300 (19.9%) were using a biologic. Of those, 82.0% (n= 246) 
were in China. Relative to China, patients were less likely to use biologics in Brazil 
(OR 0.21; 95% CI: 0.13, 0.36) and Russia (OR: 0.29, 95% CI: 0.18, 0.46; ps< 0.001). Higher 
CCI was associated with use of biologics (OR: 1.18, 95% CI: 1.10, 1.26; p< 0.001), 
as were higher OOP costs (OR: 2.37, 95% CI: 1.04, 5.42; p< 0.05) compared to no 
OOP costs. Fear of needles was positively associated with biologic use (OR: 1.57, 
95% CI: 1.18, 2.09; p< 0.01). No other covariates were significant. cOnclusiOns: 
Country was by the strongest predictor of biologic use in patients with autoim-
mune conditions in emerging markets, but higher costs and more comorbidities 
were associated with biologic use across emerging markets.
PSY66
diSeaSe StatuS, treatmentS and outcomeS oF PatientS with 
ankYloSing SPondYlitiS receiVing their FirSt Biologic in the united 
StateS and euroPean union
Narayanan S.1, Baskett A.2, Lu Y.2, Hutchings R.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To compare the disease status, treatments and outcomes of patients 
with AS receiving their first biologic in UK, Germany, France, Italy and Spain (5EU) 
with the US. MethOds: A multi-country multi-center medical chart-review study 
of AS patients was conducted between October-December 2012 among physicians 
(rheumatologists: 5EU: 97%, US: 99%) in hospitals and private practices to collect 
de-identified data on AS patients who were recently treated with a biologic as 
part of usual care. Physicians were screened for duration of practice and patient 
volume and recruited from a large panel to be geographically representative in 
each country. Eligible AS patient charts (> 2) were randomly selected from a sample 
of prospective patients visiting each center/practice during the screening period. 
Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status/outcomes. Results: Seven hundred and ninety 
seven eligible AS patient charts (5EU:613, US: 184) were abstracted; 701 (5EU:549, 
US: 152) patients were on their first biologic (mean-age: 5EU:42.5yrs/US:42.4yrs; 
female: 5EU:16.2%/US:17.1%). Time-to-1st biologic from diagnosis (5EU:55.3months/
US:46.8months) and time-on-current biologic (5EU:31.7months/US:44.3months) 
differed between regions. Top-2 biologic treatments observed were – adalimumab 
(5EU:43%/US:35%) and etanercept (5EU:30%/US:41%). Among the top-3 reasons for 
biologic treatment initiation, ‘mechanism of action’ & ‘improve signs/symptoms’ 
were observed in both 5EU and US, whereas ‘positive personal experience’ (5EU) and 
‘prevention of structural damage’ (US) were also observed. Key lab measures docu-
mented were: ESR (5EU:17.4mm/h, US:20.9mm/h) and CRP (5EU:8.8mg/dl, US:2.7mg/
dl). Current disease severity per physician-judgment (mild:moderate:severe) was: 
5EU-63%:32%:6%, US-62%:34%:5%. Among patients with available data, current HAQ 
(5EU:1.3, US:0.8), BASDAI (5EU:2.9, US:3.4), VAS provider score (5EU:2.9, US:2.5), VAS 
patient score (5EU:3.0, US:2.7), Swollen Joint Count (5EU:1.3, US:0.5), and Tender Joint 
Count (5EU:2.0, US:0.9) differed across regions. cOnclusiOns: Among AS patients 
receiving their first biologic, disease severity differed between 5EU and US, with 
patients in 5EU with relatively higher burden and poorer outcomes.
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National Health System. The objective of this research is to analyze the differ-
ences in adoption of BS among the different Spanish Autonomous Communities 
(Regions). MethOds: Ecologic design. A retrospective analysis of the Spanish 
2011 Health System Survey was conducted to estimate the prevalence of adult 
PWI for BS in each Region. The results were therefore extrapolated to the total 
regional adult population reported by the National Institute of Statistics for 2011. 
The total number of bariatric surgeries by Regions during 2011were retrieved 
from the database of the National Health Ministry (ICD-9-CM: 44.31, 44.39, 44.38, 
44.95 and 44.69) Results: Variation in the annual provision of BS was large, rang-
ing from 0.81% of patients with indication for Murcia, to 0.11% in Navarra. For 
the rest of Regions, the percentage of PWI operated in 2011 was: Madrid= 0.62%; 
Castilla y León= 0.60%; Aragón= 0.35%; Cataluña= 0.33%; Pais Vasco= 0.32%; Com. 
Valenciana= 0.30%; Cantabria= 0.30%; Canarias= 0.30%; Extremadura= 0.23%; 
Galicia= 0.22%; Asturias= 0.19%; Andalucía= 0.18%; Castilla La Mancha= 0.15%; 
Baleares= 0.14% and La Rioja= 0.13%. cOnclusiOns: These results raise the 
hypothesis that living in a certain Region may strongly affect the probability of 
a PWI receiving BS. In such case, this variability should be tackled, particularly 
in a country where most patients are supposed to have access to this treatment 
without any copayment. Further research with more accurate estimations and 
multilevel analysis models would be desirable to confirm these results.
PSY74
PiVotal StudieS oF orPhan medicinal ProductS – an analYSiS oF 
QualitY oF clinical eVidence
Picavet E.1, Cassiman D.2, Hollak C.E.M.3, Maertens J.2, Simoens S.1
1KU Leuven, Leuven, Belgium, 2University Hospital Leuven, Leuven, Belgium, 3University of 
Amsterdam, Amsterdam, The Netherlands
Objectives: Recent debate on the long-term effectiveness of some orphan medic-
inal products (OMPs) led us to question whether the initial standards for clinical 
evidence for OMPs, set by EMA at the time of marketing authorization, are too low. 
Therefore, the aim of this study was to quantitatively evaluate the characteristics 
and quality of clinical evidence that is presented for OMPs to obtain marketing 
authorization in Europe. MethOds: We quantitatively assessed the characteris-
tics and quality of clinical evidence of the pivotal studies of 64 OMPs as described 
in the European Public Assessment Report and/or the Scientific Discussion docu-
ment prepared by the Committee for Human Medicinal Products of the EMA using 
a new and validated instrument. Results: The 64 OMPs were altogether author-
ized for 78 orphan indications, for which 117 studies were identified as ‘pivotal’ 
or ‘main’ studies. In approximately two thirds of the studies, the allocation was 
randomized (64.8%) and a control arm was used (68.5%). Half of the studies applied 
some type of blinding. Only a minority (26.9%) of the studies included a Quality-
of-Life (QoL) related endpoint, of which a third claim an improvement in QoL. 
Upon analyzing the quality of reporting, we found that some aspects (i.e. the 
endpoints, the sampling criteria, and the interventions) are well described, 
whereas other items (i.e. a description of the patients and of potential biases) 
are not reported for all studies. cOnclusiOns: In conclusion, the pivotal studies 
that are the basis for marketing authorization of OMPs are a cause for concern, 
as they exhibit methodological flaws. Additionally, there are shortcomings in the 
reporting of those studies that complicate the interpretation. A more demanding 
regulatory process for OMPs is needed to guide evidence-based clinical decision-
making.
PSY75
how to determine Size oF Patient PoPulation when the right data 
iSn’t there?
Stuchiner A.
PAREXEL, New York, NY, USA
Objectives: As costs of health care continue to rise, payers need to quantify the 
potential patient population for a new treatment. In the case of a novel treatment 
for intractable pain that would be for end of life cancer patients, it was necessary 
to consider alternative methods for calculating the potential patient population 
size. This study determined different approaches for identifying patient subpopu-
lations in cancer for ‘end-of-life’ pain therapies MethOds: PAREXEL conducted a 
literature search on the number of cancer pain patients with intractable pain. Data 
was found on cancer patients with pain but not those at the end of their lives with 
intractable pain. Alternative measures were considered, and cancer mortality data 
was identified as a surrogate for end of life cancer patients. The WHO’s guidelines 
on cancer pain estimate that 10 to 25% of cancer pain patients have intractable 
pain. Based on such surrogate measures, we were able to determine an estimated 
number of cancer patients with intractable pain at the end of their lives. Results: 
Prior to this study, the target patient population was estimated to be 156,000 in 
the US and an equivalent number in Germany, UK, Spain and France. However, 
based on the surrogate measures, the results were much lower: 30,000 in the US 
and 31,000 in the 4 EU countries. These numbers were validated by interviewing 22 
pain clinicians in the US and EU and 23 payers in the US and EU. cOnclusiOns: 
By providing payers with accurate estimates of potential patient populations they 
will be better able to determine the cost implications of covering novel treatments. 
Given that the care provided to patients at the end of their lives is usually signifi-
cantly higher than at any other time, treatments for end of life care have economic 
implications for payers.
PSY76
coSt-minimization oF maBthera intraVenouS VerSuS SuBcutaneouS 
adminiStration
Bax P., Postma M.J.
University of Groningen, Groningen, The Netherlands
Objectives: To identify and compare all costs related to preparing and administrat-
ing MabThera for the intravenous and subcutaneous formulations in Dutch hema-
tological patients. The a priori notion is that the costs of subcutaneous MabThera 
In 2011, a total of 630 products (all therapeutic classes) were prescribed. The most 
often other prescribed classes in 2011 were gastrointestinal tract products (14.60%), 
cardiovascular agents (11.11%) and antimicrobial products (9.52%). The most fre-
quently prescribed subclasses were HMG-CoA reductase inhibitors (statins), anal-
gesic combinations, non-selective COX-inhibitors and selective serotonin re-uptake 
inhibitors. The total amount claimed from the medical insurance scheme for all the 
products was R73013.71, however, only R37553.24 was paid out. Appetite suppres-
sants were excluded from patients’ medical insurance benefits. cOnclusiOns: A 
limited number of strictly regulated appetite suppressants were prescribed. Appetite 
suppressants that patients can buy over-the-counter were not included in this study. 
Pseudoephedrine has recently been rescheduled to be more strictly controlled due 
to its abuse potential. Further consumer studies on appetite suppressants which 
include clinical information will provide a useful insight into the role of these prod-
ucts in weight loss efforts.
PSY71
analYSiS oF the reimBurSed PSoriaSiS market in hungarY Between 
2007 and 2011
Ecseki A., Nagy Z.B., Becsi R., Gerencsér Z., Rozsa P., Toth I.
MediConcept Ltd., Budapest, Hungary
Objectives: Psoriasis is a chronic skin disease of scaling and inflammation, typi-
cally characterized by erythematous papules and plaques with a silver scale. In 
Hungary, approximately 150.000 – 200.000 people are affected. We sought to evalu-
ate the available reimbursed psoriasis treatment options, the economic impact 
of the disease, and in general we attempted to see beyond the market trends and 
patients characteristics observed in the analysed dataset. MethOds: Data were 
derived from the nationwide dataset of the Hungarian National Health Insurance 
Fund Administration, the single health care financing agency of Hungary. Data 
were evaluated according to sex, age, geographical region, type of care and specialty 
of the prescribing physician. The analysis covers data of all reimbursed pharma-
ceuticals and other medical services between 1 January 2007 and 31 December 
2011. Results: The median age was between 51 and 55 years. A bimodal age of 
onset has been recognised in several large studies, but in this patient cohort peo-
ple between the ages of 30 and 69 were overrepresented. We found no significant 
deviation between counties, but there is a clear seasonality in the data. During 
each year of the analysed period the number of patients who redeemed at least 
one reimbursed drug fell short compared to the prevalence based estimates. At 
any given time close to 80% of the patients did not receive any reimbursed treat-
ment and the number of sold packages continuously decreased over the 5-year 
period. The introduction of biologic treatments also significantly affected the mar-
ket. cOnclusiOns: To our knowledge, no systematic empirical research exists 
addressing the question of how psoriasis market changed over the time in Hungary. 
The data suggest relatively poor adherence to treatment regimens frequently seen 
and documented in other studies as well.
PSY72
utilization PatternS For treatment with Strong oPioidS For 
chronic Back Pain in germanY
Theidel U.1, Mittendorf T.1, Mueller-Schwefe G.H.H.2, Ueberall M.A.3
1Herescon GmbH, Hannover, Germany, 2Deutsche Gesellschaft für Schmerzmedizin e.V., Oberursel, 
Germany, 3Institut für Neurowissenschaften, Algesiologie und Pädiatrie, Nuernberg, Germany
Objectives: Although opioids are a well-accepted and effective method for pain 
management, it is still a challenge for physicians to find adequate treatment 
schemes in non-malignant pain. Inadequate treatment might impact quality of 
life and induce social and psychological problems. Aim of this survey was to describe 
treatment patterns of chronic back pain (CBP) in Germany. MethOds: In a cross-
sectional, non-interventional survey n= 4,283 German physicians were asked to 
report experiences with strong opioids in CBP. Statistical analysis was performed to 
analyze relationships between strong opioids and potential side effects. Results: 
The majority of physicians (54.4%) at least partly accept strong opioid therapy in CBP 
noting treatment benefits in 69.6%. Most prescribed therapies are non-opioids like 
NSAIDs/COX-2 (55.1%) and physiotherapy (47.7%). 22.7% of all CBP receive strong opi-
oids (26.0% fentanyl, 19.9% oxycodone/naloxone, 17.8% oxycodone, 13.9% hydromor-
phone, 13.8% burprenorphine, 13.7% morphine, 7.3% tapentadol, 1.8% L-methadone). 
16.5% are treated in monotherapy, 23.6% with multimodal treatment. 67.5% show 
a reduction in pain intensity ≥ 50%. 25.8% need strong opioids for longer than 12 
months. 26.2% need an increased dosage. Furthermore, 20.2% of patients experience 
a decrease in efficacy, which leads to opioid rotation (15.1%). 23.4% have persistent 
side effects (25.3% never, 46.4% temporary) wherefore 16.1% switch and 15.2% with-
draw the treatment. Most side effects are observed near start of therapy, with con-
stipation being the most common and resistant side effect (49.1%). After treatment 
discontinuation, pain status is considerable worsened in 34.3%. Correlation analysis 
shows that morphine has the highest probability of side effects when compared 
to oxycodone and oxycodone/naloxone. cOnclusiOns: Although physicians see 
the medical need, CBP patients seem not to be overly treated with strong opioids. 
Obviously, morphine is not the treatment of first choice. Treatments chosen strongly 
depend on physician specialty. As anticipated, constipation is the most common 
and resistant side effect.
PSY73
VariaBilitY oF clinical Practice For Bariatric SurgerY in SPain
Espallardo O., Busutil R.
Johnson & Johnson Medical, Madrid, Spain
Objectives: Geographical variations in medical practice are expected to be small 
when the evidence about a particular technology is abundant. This would be the 
case of bariatric surgery (BS), which has been demonstrated to be an effective 
intervention to promote weight-loss in patients with indications for this pro-
cedure (PWI). Moreover, BS has recently proven to be cost-effective and drive 
long-term savings, compared to a “do-nothing” intervention, for the Spanish 
